Japan· JP-3929409A2046
スガマデクスナトリウム
A sugammadex product containing スガマデクスナトリウム, registered in Japan by ヴィアトリス・ヘルスケア, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Sugammadex is registered in 18 of 19 countries.
Countries holding a registration under ATC V03AB35 (sugammadex), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 10 of them publish a price we can compare per daily dose
Sugammadex · ATC V03AB35
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- スガマデクスナトリウム
- Manufacturer
- ヴィアトリス・ヘルスケア
- Country
- Japan (JP)
- ATC code
- V03AB35
- ATC class
- Sugammadex
- Defined daily dose
- 0.28 g, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
34 interactions on record for sugammadex.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sugammadex · interactions on record
34 records
- 14 severe
- 20 moderate
Most severe, free to view
- IUP aus Plastik mit GestagenG02BA03severe
- Drospirenone and ethinylestradiolG03AA12severe
- NorethisteroneG03AC01severe
- LevonorgestrelG03AC03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under V03AB35
Sugammadex, as other registers publish it.
- GermanyAreversinPharmaselect International Beteiligungs Gmbh
- CzechiaBLOVOVANVianex S.A., Nea Erythrea
- CzechiaBLOVOVANVianex S.A., Nea Erythrea
- PolandBridionMerck Sharp & Dohme B.V.
- FinlandBridionMerck Sharp & Dohme B.V.
- IcelandBridionMerck Sharp & Dohme B.V.*
- DenmarkBridionMerck Sharp & Dohme B.V.
- United StatesBRIDIONMerck Sharp & Dohme LLC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fe67afa7-11c9-48e3-9e8d-03f1060fffba GET /v1/drugs/fe67afa7-11c9-48e3-9e8d-03f1060fffba?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５００ｍｇ５ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3929409A2046",
"category": "注射薬",
"price_yen": 6177,
"generic_name": "スガマデクスナトリウム",
"product_name_jp": null,
"therapeutic_class": "3929",
"transitional_expiry": null
}See everything about sugammadex.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.